1 **TITLE PAGE**

- 2 Protocol for a Feasibility study incorporating a Randomised Pilot Trial with an Embedded Process Evaluation
- and Feasibility Economic Analysis of ThinkCancer!: A primary care intervention to expedite cancer diagnosis 3
- in Wales 4
- 5 27 November 2020, Version 1.0
- 6 Stefanie Disbeschl¹, Alun Surgey¹, Jessica L Roberts¹, Annie Hendry¹, Ruth Lewis¹, Nia Goulden², Zoe Hoare²,
- 7 Nefyn Williams³, Bethany Fern Anthony⁴, Rhiannon Tudor Edwards⁴, Rebecca-Jane Law¹, Julia Hiscock¹, Andrew
- 8 Carson-Stevens⁵, Richard D Neal⁶ and Clare Wilkinson¹
- 9 ¹North Wales Centre for Primary Care Research (NWCPCR), Bangor University, Cambrian 2, Wrexham
- 10 Technology Park, Wrexham, LL13 7YP, UK
- 11 ²North Wales Organisation for Randomised Trials in Health (NWORTH), Bangor University, The Normal Site,
- Holyhead Road, Gwynedd, LL57 2PZ, UK 12
- 13 ³Department of Primary Care and Mental Health, Institute of Population Health, University of Liverpool,
- 14 Liverpool, L69 3GL, UK
- 15 ⁴Centre for Health Economics and Medicines Evaluation (CHEME), Bangor University, The Normal Site,
- Holyhead Road, Gwynedd, LL57 2PZ, UK 16
- 17 ⁵Division of Population Medicine, School of Medicine, Cardiff University, UHW Main Building, Heath Park,
- Cardiff, CF14 4XN, UK 18
- 19 ⁶Academic Unit of Primary Care, Leeds Institute of Health Sciences, University of Leeds, Worsley Building,
- 20 Leeds, LS2 9NL, UK
- 21 **Corresponding author:**
- 22 Stefanie Disbeschl stefanie.disbeschl@bangor.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Background

Relative to the rest of Europe, the UK has relatively poor cancer outcomes, with late diagnosis and a slow referral process being major contributors. General practitioners (GPs) are often faced with patients presenting with a multitude of non-specific symptoms that could be cancer. Safety netting can be used to manage diagnostic uncertainty by ensuring patients with vague symptoms are appropriately monitored, which is now even more crucial due to the ongoing Covid-19 pandemic and its major impact on cancer referrals. The ThinkCancer! Workshop is an educational behaviour change intervention aimed at the whole general practice team, designed to improve primary care approaches to ensure timely diagnosis of cancer. The workshop will consist of teaching and awareness sessions, the appointment of a Safety Netting Champion and the development of a bespoke Safety Netting Plan, and has been adapted so it can be delivered remotely. This study aims to assess the feasibility of the ThinkCancer! Intervention for a future definitive randomised controlled trial.

Methods

The ThinkCancer! study is a randomised, multisite feasibility trial, with an embedded process evaluation and feasibility economic analysis. Twenty-three to 30 general practices will be recruited across Wales, randomised in a ratio of 2:1 of intervention versus control who will follow usual care. The workshop will be delivered by a GP educator and will be adapted iteratively throughout the trial period. Baseline practice characteristics will be collected via questionnaire. We will also collect Primary Care Intervals (PCI), Two Week Wait (2WW) referral rates, conversion rates and detection rates at baseline and six months post-randomisation. Participant feedback, researcher reflections and economic costings will be collected following each workshop. A process evaluation will assess implementation using an adapted Normalisation Measure Development (NoMAD)

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

questionnaire and qualitative interviews. An economic feasibility analysis will inform a future economic evaluation. **Discussion** This study will allow us to test and further develop a novel evidenced-based complex intervention aimed at general practice teams to expedite the diagnosis of cancer in primary care. The results from this study will inform the future design of a full-scale definitive phase III trial. Trial registration: intended registry: clinicaltrials.gov **KEYWORDS** Early cancer diagnosis, feasibility, primary care, general practitioners, safety netting, health economics, process evaluation **INTRODUCTION Background** Cancer survival in the UK lags behind other western countries. Referral rates and adherence to guidelines are lower,^{2,3} primary care providers (PCPs) are less likely to take action on potential cancer symptoms⁴ and cancer tends to be diagnosed at a later stage, often only after patients have presented to acute or emergency secondary care services.3 Compared with the rest of Europe, the UK has relatively low one-year survival, which could be due to later diagnosis.5 Timely diagnosis is key to improving cancer outcomes⁶ and cancer survival.⁷ Earlier diagnosis could also reduce the proportion of cancer patients diagnosed through emergency care. Early diagnosis is a rising priority in cancer policy, ^{6,8} because it is cost-effective¹ and the incidence of cancer is increasing. ⁹ Policies in Wales emphasise the

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

importance of early diagnosis, and recognise that increasing demand and a slow referral process are significant barriers to a quick cancer diagnosis.³ Following the implementation of these policies, progress has been slow, with late stage diagnosis continuing to be an issue. 10 The timely diagnosis of cancer has become even more crucial as we enter a period in which primary care and cancer management has changed dramatically due to the ongoing Covid-19 pandemic. 11-13 Early figures have shown a 76% decrease in urgent cancer referrals across the UK and predict a 20% increase in excess deaths for patients with newly diagnosed cancers. 14 There has also been a drop in the number of patients presenting to primary care¹⁵; patients and clinicians may have concerns due to a perceived risk of contracting Covid-19 in a healthcare setting. 14 Some patients may also attribute symptoms that could be cancer to Covid-19 and therefore, may avoid health services altogether. 11,13,16 General practitioners (GPs) may also be reluctant to refer patients on to secondary care in order to minimise infection risk.¹⁵ The increased use of remote consultation as a result of the pandemic will also have implications for the early diagnosis of cancer, as important consultation techniques such as the use of visual cues and physical examination may be impacted. These issues highlight the everimportant need of safety netting, and Covid-related considerations will need to be made by GPs in their safety netting approaches.¹¹ Primary care providers (PCPs) play a vital role in the early diagnosis of cancer. ¹⁷ A key diagnostic stage is the Primary Care Interval (PCI), which is the time from first presentation to a GP with a symptom that could be cancer, to the subsequent referral to a specialist in secondary care. 18 However, with an ever expanding role, PCPs are presented with a plethora of non-specific symptoms, of which only a small proportion are caused by cancer, and many overlap with other diseases.⁶ Furthermore, with certain cancers, patients may not present with any alarm symptoms^{6,17} which often results in a delayed cancer diagnosis.² In addition, guidelines to expedite early cancer

diagnosis are often unclear, with great variation in strategies between different GPs.¹⁹

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Rationale and previous work Clinical behaviour change interventions targeting PCPs have the potential to address barriers to suspected cancer identification and referral, and could expedite the diagnosis of cancer and improve cancer outcomes overall.²⁰ There is some evidence that educational interventions targeted at PCPs could reduce the PCI, providing they encompass a multidimensional, interactive and tailored approach. ²⁰⁻²² A recent systematic review of primary care interventions suggested that a whole-practice approach providing opportunities for peer review and feedback could have a positive effect on referral practices, in addition to existing guidelines being revisited through training and reinforcement.23 While the timely diagnosis of cancer is crucial, urgent referral can lead to over-diagnosis and over-investigation which can be harmful to the patient. 7,24 This risk is especially high if the patient presents with vague symptoms. 25 Safety netting, a tool used to manage diagnostic uncertainty, ²⁶ can address these issues by ensuring that patients with non-specific symptoms are not ignored.²⁴ Instead of immediate referral, patients are monitored according to a set step-wise investigational plan, while ensuring they are referred in a timely manner as and when required.²⁴ Although safety netting is currently recommended by national guidelines,²⁷ there are no clear recommendations on how to do it. 19,24,26 In summary, it is relevant and befitting to develop and test interventions aimed at improving the quality and consistency of primary care approaches to ensure timely diagnosis of cancer in the UK. This will require multicomponent and complex behavioural change interventions, which utilise a multidimensional, interactive, tailored, whole-practice approach. The ThinkCancer! intervention is a complex behaviour change intervention aimed at general medical practice teams, developed as part of the Wales Interventions for Cancer Knowledge and Early Diagnosis (WICKED) research programme, described in more detail elsewhere. ²⁸ It consists of an educational workshop that includes

early diagnosis and awareness sessions, evaluation of current practice-based safety netting systems and the

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

METHODS

appointment of a safety netting champion. The workshop will be led by an educational facilitator who will guide the development of a bespoke safety netting plan for each practice. The aim of this study is to assess the feasibility of delivering the ThinkCancer! intervention and conducting a future, definitive randomised controlled trial (RCT) to assess effectiveness and cost-effectiveness, in order to establish whether the intervention can be rolled out in practice. **STUDY OBJECTIVES** The objectives of this study are as follows: 1) To assess the feasibility of a future definitive RCT by monitoring recruitment and retention, outcome measure completion and reasons for decline. 2) To assess the acceptability, feasibility, and utility of the ThinkCancer! intervention as a whole, and of each of its individual components, and refining the intervention as necessary. 3) To determine the most appropriate primary outcome measure for a definitive RCT and producing means and confidence intervals for calculating effect sizes for the design of a definitive trial. 4) To describe current contextual differences, and similarities, between general medical practices and their usual safety netting practices. 5) To identify and test the methods and outcome measures for a process evaluation of a future definitive RCT. 6) To undertake a feasibility analysis of the most appropriate approach for an economic evaluation alongside a future definitive trial.

Study design

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

The feasibility study incorporates a pragmatic, multisite, two-armed, superiority, pilot RCT. There is an embedded

process evaluation and feasibility economic analysis. The unit of randomisation is the general medical practice,

and the primary clinical outcome is collected at the practice level.

The term 'feasibility' is used in accordance with the conceptual framework developed by Eldridge and

colleagues,²⁹ where it is described as an umbrella term within which pilot trials are a component. Furthermore,

the study has been designed in accordance with the MRC Framework for evaluating complex interventions.³⁰ The

trial will be conducted according to NIHR guidance,³¹ and recommendations for good practice in pilot studies.³²

The process evaluation, which will be based on a mixed-methods approach, will follow the MRC guidance for

process evaluations of complex interventions.³³ During the initial piloting or feasibility testing stage of an

intervention, process evaluation has a vital role in understanding and planning the future potential

implementation of the intervention and optimising its design and evaluation.³³

The feasibility economic analysis will explore the appropriate future perspective of analysis; most appropriate

methods of gathering costs; range and value of outcome measures, and undertake a feasibility budget impact

analysis of the ThinkCancer! intervention developed through a range of blended methods that it is delivered

online (either in a live format or pre-recorded) or face-to-face in general practices across north Wales.

This study protocol was developed in line with the Standard Protocol Items: Recommendations for Interventional

Trials (SPIRIT) guidelines³⁴; the SPIRIT checklist (appendix 1) and the schedule of procedures can be seen in Table

1. The SPIRIT checklist has been adapted in accordance with the CONSORT extension to pilot and feasibility

trials.35

Table 1: SPIRIT protocol schedule of procedures for the ThinkCancer! study

	STUDY PERIOD					
	Pre- allocation	Baseline Assessment	Randomisation	Intervention Period	2 Month Follow-up	6 Month Follow-up
TIMEPOINT	-t ₁	0	t ₁	t ₂	f ₁	f ₂
ENROLMENT:						
Eligibility screen	Х					
Invitation email	X					
Practice information and consent	X					
Baseline questionnaire		X				
Allocation			X			
INTERVENTION:						
Control group: usual practice			•			•
Intervention group: ThinkCancer! Workshop				X		
ASSESSMENTS:						
Collection of clinical outcome measures			X			X
Observation during workshops				X		
Workshop participant evaluation forms				X		
Workshop delivery staff logs				X		
Health economics data collection sheets				X		
Endline questionnaire						X
Adapted NoMAD questionnaire					•	•
Telephone Interviews (practice staff)					•	•

Study setting

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

The setting for this study is primary care. The intervention will be delivered in-practice or online to individual general medical practices and incorporates a whole-practice approach. The trial will be conducted across Wales and practices will be recruited from all seven Welsh health boards.

Intervention

The proposed intervention, the ThinkCancer! Workshop, has four chief components. The first are two educational sessions, one for all clinical staff (the 'early diagnosis' session) and one for non-clinical but patientfacing staff (the 'cancer aware' session). The early diagnosis session is delivered as a teaching seminar with learning outcomes focussed on NICE NG12 Suspected Cancer: recognition and referral guidelines²⁷, hot topics exploring the harder to recognise cancer presentations and consultation-level safety netting. As a proposed aid to support and formalise safety netting, a new tool - the Symptom Safety Netting Action Plan (SSNAP) will be introduced. This session will also see the introduction of the ThinkCancer! Handbook, which will contain all the resources used in the workshop as well as external resources regarding early diagnosis and safety netting, such as NICE guidance and online learning resources. The cancer aware session is less formal with more convenor-led discussion around cancer red flag symptoms that non-clinical staff may encounter. The secondary aim of this session is to gauge and explore issues and norms around raising concerns within the practice team. The third session (the 'safety netting session') involves the two final components of the intervention, the co-production of a bespoke Cancer Safety Netting Plan (CSNP) and appointment of a Cancer Safety Netting Champion (CSNC). This session is attended by a combination of clinical and administrative staff who will be involved in the design and implementation of a new plan. Members of the research team will deliver the intervention; the GP Educator (AS) will oversee the workshop, supported by up to two researchers. The workshop was originally designed to be delivered face-to-face in participating practices during practices' allocated protected time for educational and professional development. However, due to the ongoing Covid-19 pandemic, the workshop has been adapted into a digital format and can

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

be delivered in one of three ways: (i) fully remote and live via online conferencing platforms; (ii) blended delivery, where practices are offered a combination of pre-recorded versions and live remote delivery of the different sessions; and (iii) face-to-face in the practice, as originally intended, if the situation allows. Practices that opt for the blended delivery of the workshop can choose to receive pre-recorded videos of sessions 1 and 2, presented by the GP Educator, allowing participants to engage with the materials in their own time. The final session, which focuses on the Cancer Safety Netting Plan, will still need to be delivered as a live session due to its interactive components. There will be flexibility to work with the practice to allow the bespoke design of the workshop format to improve the reach of the intervention. Practices receiving the intervention in any of the remote forms will be sent all of the workshop materials, including the handbook and SSNAP tool, via post. If there is the possibility to deliver the workshop face-to-face, materials will be distributed in the practice at the beginning of the workshop. Practices randomised to the control group may also receive the pre-recorded videos at the end of the study period, along with the intervention materials.

A logic model (figure 1) has been developed to describe the intervention components and how they link to the

Figure 1: ThinkCancer! Logic model

Outcome Measures

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

The outcomes that will be reported in this feasibility study are as follows:

intended outcomes and will be adapted throughout the study period.

- 197 Recruitment will be assessed quantitatively by capturing the numbers of practices
- 198 approached,
- 199 interested in participating,
- 200 consented,
- 201 randomised

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

A description of the excluded practices will be included to help identify potential future eligibility criteria and reasons for non-participation will be sought. Retention will be assessed quantitatively by the numbers of practices providing both baseline and follow up data. Data on individual practice characteristics will be collected to: describe the studied sample, identify potential effect modifiers, allow identification of 'usual practice' The overarching goal of the ThinkCancer! Intervention is to change GPs' and primary care practices' behaviours and systems, encouraging them to be more cancer-aware and act sooner on clinical presentations that could be cancer, or more effectively safety net cases where concern exists but criteria for immediate referral are not met. The proposed primary clinical outcomes for the definitive RCT relate to the early referral of suspected cancer. They include the two-week wait (2WW) referral rate and the PCI. The 2WW referral rate is defined as the crude rate of 2WW referrals multiplied by 100,000 and divided by practice list size.³⁶ The PCI is defined as the time between the date of first presentation and the date of referral.¹⁸ Secondary clinical outcome measures include the conversion rate and the detection rate. The conversion rate is defined as the "proportion of 2WW referrals that are subsequently diagnosed with cancer" and the detection rate consists of the "proportion of new cancer cases treated who were referred through the Two Week Wait route", 36 also known as the sensitivity. 37 These measures will allow us to further explore potential clinical outcomes. Although it is unlikely that we will detect a difference in the clinical measures in the feasibility study due to the small sample and short duration of follow-up, we do expect these outcome measures to be affected by the

ongoing Covid-19 pandemic. However, the feasibility of using these outcomes will be assessed.

Feasibility of using potential clinical primary outcomes, 2WW referral rate, PCI, conversion rates and detection

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

rates, will be assessed quantitatively by determining: ability to collect/capture data from the practices, based on completion rates of data collection forms ability to extract relevant data from routinely collected data at Health Board level and from individual practices, based on whether we are able to obtain the data via Health Board contacts and whether these data are comparable with those collected by individual practices suitability and variability of the data to perform as primary outcome measures for clinical effectiveness Acceptance, adherence to and fidelity of the intervention will be assessed by: reviewing participant views, reflections and perceptions expressed via post-workshop feedback forms and interviews post-workshop reflections from the intervention delivery staff the ability to organise/schedule and deliver workshops the number of practices that actively nominate a safety netting champion the number of practices that demonstrate the use of the safety netting plan To inform the process evaluation for the future definitive trial, we will: evaluate how to scale up for any future process evaluation, determine the acceptability and appropriateness of the interview process identify barriers and facilitators to successful implementation, test measures for assessing reach, dose and fidelity of the intervention For the health economics component we will: determine the feasibility of collecting data relating to the costing of the intervention via costings forms identify variables necessary for the design of a future economic evaluation alongside a definitive trial

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

review relevant literature on the cost-effectiveness of online and mixed-methods Continuing Professional Development (CPD) programmes for health professionals in a community setting consult the DIRUM database³⁸ to identify the most appropriate way of capturing the costs of the ThinkCancer! Intervention (online delivery and mixed-methods delivery). Adaptations to the intervention and logic model will also be recorded throughout the trial period. Progression criteria The outcome measures relating to recruitment, retention and adherence/fidelity will be assessed using RAG criteria, as defined below: 1. Confirmation of adequate recruitment for a definitive trial at practice level. Go: 20 or more general medical practices recruited; Review: 15-19 recruited; Stop: < 15 practices recruited. 2. Confirmation of adequate retention for the definitive trial at practice level. Go: 80% or more practices retained; Review: 65-79% practices retained; Stop: < 65% practices retained 3. Confirmation of adequate fidelity of the intervention. Go: 80% or more of all intervention sessions delivered, Review: 50-79% of all interventions delivered; Stop: < 50% of interventions delivered. 4. Confirmation of adequate fidelity at individual practice staff level: From each general practice: a. at least 50% of the clinical staff should attend the workshops; b. at least 50% of the administrative staff should attend the workshops, comprising at least 50% of the reception and secretarial staff as well as the practice manager. c. Staff who do not attend the training should have the information cascaded to them by a member of the team who did attend the training. At least 75% of the staff should receive the training either directly or indirectly. Progression criteria relating to obtaining data regarding completion of outcome measures will be assessed using the following progression criteria:

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

1. Routine data. Go: data from 70% or more practices obtained; Review: data from < 70% of practices obtained 2. Individual data. Go: data from 70% or more of individuals of each practice obtained; Review: data from < 70% of individuals from each practice obtained These criteria would reflect the potential outcomes for exclusion/inclusion at a full definitive trial stage rather than prevention of the study progressing. Sample size We aim to recruit 23-30 general medical practices, depending on the ease of recruitment, using a randomisation allocation ratio of 2:1 of intervention versus control. Randomising in preference to the intervention will allow us to iteratively develop the intervention more effectively. As this is a feasibility study, there is no requirement for a formal power calculation. This study is not intended to be powered to identify a clinically meaningful difference between the intervention groups for the primary outcome measures. Rather this study aims to provide robust estimates for the likely recruitment and retention rates, and give an indication of the potential variability in the proposed outcome measures, which will in turn be used to inform the power calculation for a future definitive RCT. This is discussed further under statistical analyses. **Recruitment and consent** Recruitment General practices will be identified through contact details publicly available via practice websites and through contact lists provided by the health boards across Wales. Practices will be invited to participate using a standardised invitation via email addressed to the practice manager, along with information about the study.

Practice managers will be asked to consult with their team and indicate their interest in participating in the study

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

by responding to the email. They will also need to advise of their practice's availability for potential workshop dates. If no response to the initial email is received, a reminder email will be sent followed by a telephone call. A participant flow diagram can be seen in figure 2. Figure 2: Participant flow diagram Practices that take part in the study will be financially reimbursed for their time. We will establish contacts within regional primary care clusters, with health board staff and with R&D departments in order to maximise potential recruitment opportunities. The recruitment methods will be continually assessed and iteratively developed to determine the most appropriate recruitment strategy for a future definitive RCT. Eligibility to participate As feasibility is the main objective of this study, all types of general medical practice will be eligible for inclusion. This will aid intervention refinement and allow for a better understanding of what is feasible across a range of practices, and also why some practices may not be able to take part. Inclusion Any general practice in Wales is eligible for inclusion. The target audience for the intervention, based on a 'whole team approach', includes all practice staff members. These may include, for example, GPs, nurse practitioners, nurses, health care support workers (HCSWs), practice managers, administrators, receptionists or any other practice staff, clinical and non-clinical. We would aim to include any new forms of primary care organisations such as managed GP practice networks, or other general medical practice amalgamations, as well as traditional GP partnerships. However, some of these may be unstable practices with no regular GP staff, and as such, they may be difficult to recruit or find it difficult to participate. Practices participating in other research are also eligible for inclusion; they will be asked to notify us of any cancer-related studies they may be participating in via the baseline questionnaire.

rint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the prep perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

Exclusion There are no exclusion criteria. Consent Practice managers will be sent more detailed study information in the form of a 'Research Information Sheet for Practices' (RISP) and a link to an online baseline practice questionnaire after they have expressed an interest to take part in the study. Participating practice managers will need to indicate that they have read the study information and have agreed with consent statements on the first page of the electronic questionnaire before they can proceed. Prior to the commencement of the ThinkCancer! workshop, Participant Information Sheets (PIS) will be provided by members of the research team and written consent will be obtained from all participating members of staff. This will include consent to use anonymised data recorded on paper or audio-file during workshops and workshop feedback forms. At this time point, participants will also be given the option to provide their contact details should they be happy to be contacted for a telephone interview. Those who indicate that they would like to take part will be contacted at least two months after the intervention. Participants from practices randomised to the control arm, who do not take part in a workshop, will also have the opportunity to take part in a telephone interview and will be sent an invitation letter via their practice manager. Response to interview invitations and supplying of contact details will be taken as consent to be contacted and informed consent will be obtained verbally at the time of interview. NB Although we will initially contact practice managers, and they will most likely be the person who completes the questionnaire, this task may be delegated to another member of the practice team with a particular interest in the study. Pre-trial pilot A local practice, known to the research team, has agreed to participate in a ThinkCancer! pilot workshop prior to

full rollout of the feasibility study. The practice is an urban, large 12,000 patient training practice in a moderately

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

deprived region of North East Wales. Data will not be collected or recorded for trial purposes and feedback from those participating will only be used to refine the intervention prior to its delivery across recruited practices. Randomisation and blinding The general medical practice will be the unit of randomisation. Randomisation will be achieved online, through the remote randomisation centre at the North Wales Organisation for Randomisation Trials in Health (NWORTH) at Bangor University. The randomisation system will use a dynamic adaptive allocation algorithm³⁹ to achieve randomisation. ThinkCancer! is an open trial where blinding of participants, researchers and the statistician is not possible due to the nature of the intervention and 2:1 ratio for randomisation. Withdrawal criteria Practices (and individuals within a practice) will be free to withdraw from the trial at any time, and their right to refuse participation will be respected throughout. We will seek to understand their reasons where possible. In terms of the primary outcome measures, as long as it is possible to collect the data, intention-to-treat analysis will be utilised, whether or not the intervention was received or adhered to. Data collection The feasibility study will be used to rehearse data collection approaches and assess their ease of use. Data will be collected at time-points specific to each item and depending on the type of data. All data collected in this study will be anonymised. Proposed clinical effectiveness outcomes Data relating to the proposed primary outcomes for the future definitive RCT will be collected at baseline and 6 months after randomisation. Two week wait referral data and PCI data will be collected directly from participating practices via Case Report Forms containing full instructions on how to extract the data from practice IT systems. We will work with the Practice Manager, CSNC or other delegated individuals to achieve this. It is recognised that this is likely to be too short a follow-up period for meaningful differences to be observed, but perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

the main purpose in this case will be to test the feasibility of collecting the data in this way. Additionally, we will explore the availability of 2WW data at health board level.

Practice Questionnaires

The baseline and endline practice questionnaires will be available online to both intervention and control practices and are to be filled out by the practice manager or other designated person, ideally in collaboration with the practice team; SurveyMonkey™ will be the most likely platform. The questionnaires will consist of closed questions and some open, free-text questions, and will be used to collect data for each individual practice on the practice characteristics and current systems, and existing practice systems relating to cancer diagnosis and safety netting. The baseline data may be used to inform some workshop planning - i.e. workshop content and delivery may be tailored to some extent to suit individual practice needs and circumstances. Further process evaluation data will also be collected from the practice questionnaires as they will incorporate questions exploring contextual factors known to influence the success of quality improvement approaches used to improve health care.⁴⁰ The baseline questionnaire will be completed by all practices prior to randomisation. The endline questionnaire will assess any differences in practice, knowledge or systems in comparison with those measured at baseline and will be completed at 6 months post-randomisation.

Baseline measures will include the following:

- Demographic information and practice characteristics (practice size, research-accredited status, number of clinical and non-clinical staff members, whether a teaching practice, etc.)
- Practice culture (e.g. team structure, diversity of team member roles, team decision-making processes)
- Practice knowledge with regards to safety netting and cancer awareness
- Current safety netting systems in place, if any, including:
 - What systems are in place
 - How widely they are used within the practice
 - How safety netting issues are communicated:

385 Between clinicians 386 To the wider practice team 387 To patients 388 How safety netting is recorded 389 Feasibility and piloting data 390 Recruitment, retention and questionnaire completion numbers will be recorded throughout the trial. 391 Spreadsheet systems will be put in place to record practice responses and to track their progress in the trial (e.g. 392 number of practices approached, whether they have responded to the initial invitation, whether they have 393 agreed to be randomised, etc.). Separate spreadsheets will also record feasibility data relating to the workshop 394 itself, such as participant numbers. 395 Post-workshop reflections and participant feedback 396 Data specific to the intervention will be collected via participant feedback and observation and reflections of the 397 research staff. Participant feedback forms will be distributed to practice staff; these can be completed in paper 398 format or online. Responses will be requested using a combination of Yes/No choices, Likert scales and free-text 399 comments. The questions will cover a number of areas including acceptability, usefulness, learning outcomes 400 and the potential to change practice.41 401 Relevant ad hoc communications with practices throughout the study will also be collected on a spreadsheet, 402 which may contribute to understanding the intervention in terms of what works, why and how. 403 The same research team members will deliver the intervention in all practices; their observations will be 404 collected and will inform any refinements of the intervention. Observations and reflections recorded by the 405 research team may provide valuable data on the potential effects of contextual factors, site-by-site and 406 component-by-component measures, and the appropriateness of individual questions included in the practice 407 questionnaires. They will also describe the cancer safety netting plan proposed by the practice and whether the 408 SSNAP tool is used.

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

The researchers will keep a diary, which will include a record of any modifications made to the intervention and data collection methods. Health economics Health economics data collection sheets will be completed by the researchers following each workshop, and costings specific to the practice will be recorded. We will also use the feedback forms to determine staff roles within the practice for costing purposes. *NoMAD instrument* At least two months after the intervention, participants who consented to be contacted will be sent a link to complete an adapted Normalisation Measure Development (NoMAD) instrument.⁴² This will assess the implementation of the cancer safety netting plan using Normalization Process Theory (NPT) principles, which may or may not include the SSNAP tool depending on uptake. Telephone interviews We will conduct qualitative telephone interviews lasting up to 30 minutes with a purposive sample of up to 45 clinical and non-clinical practice staff. Practice staff in both arms of the trial will be eligible to participate in the interviews as they will be invited to give feedback on all aspects of the trial process including the intervention where appropriate. The qualitative interviews are designed to achieve an in-depth understanding of the views and perceptions of practice staff involved in the trial. The interviews will allow participants to explain how they were able to utilise aspects of the trial and how they worked in practice. Informed consent will be obtained and interviews recorded and transcribed verbatim. The interviews will be semi-structured and will follow a predefined topic guide, although not every participant will be engaged with every section of the topic guide (i.e. only the specific areas of the topic guide that are relevant to an individual's role and experience will be explored). Topics may include acceptability, safety netting, data collection, uptake of the intervention and SSNAP tool and implications. These interviews will occur at least two months after the intervention has taken place; control

practices will be invited two months post-randomisation.

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

Adverse events A risk assessment has found this trial to be low risk. Non-serious adverse events will not be collected. However, Serious Adverse Events (SAEs) will be reported that could be related to the intervention, as decided by the Chief Investigator (CI), and in line with current ICH-GCP Standard Operating Procedures.⁴³ SAEs are defined as follows: "...an untoward occurrence that (a) results in death; (b) is life-threatening; (c) requires hospitalisation; (d) results in persistent or significant disability or incapacity; (e) consists of a congenital anomaly or birth defect; or (f) is otherwise considered medically significant by the investigator"43 We do not expect any related SAEs for this study. Data analysis Quantitative analysis A fully documented statistical analysis plan will be prepared by a registered trials unit and agreed by the coinvestigators and approved by the trial governance structure, which will be known as the Trial Steering Committee (TSC). Baseline characteristics will be summarised for all practices, the intervention group and control groups separately. Feasibility and process evaluation data such as practice recruitment rate, implementation and uptake of and adherence to the intervention, and follow-up rates will be summarised and presented as percentages. Determining differences in clinical outcomes between the control and intervention is not the primary purpose of this study, therefore the focus of the results will be on the estimates of the treatment effects rather than statistical significance and as such, no hypothesis testing will be undertaken. As recommended in guidelines for good practice for the analysis of pilot studies,³² summary estimates of effects will be developed along with their 95% confidence intervals. Differences between the two comparison groups will be presented in the form of an unadjusted mean difference for continuous outcomes, and an odds ratio for binary outcomes. Exploratory

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

analysis using ANCOVA for continuous outcomes and logistic regression for binary outcomes will consider adjustment for the stratification variables in assessment of the treatment effects. Factors associated with the ability to implement the intervention will be tentatively explored using logistic regression with the focus on identifying deterministic barriers to implementation rather than probabilistic factors. The nature of the intervention may vary, directed by real-time feedback during the course of the trial and this will need to be taken into consideration during analysis. As this is a feasibility study, there will be no imputation of missing data over and above any scoring rules established for the outcomes. This information will be used to feed into the suitability and applicability of the chosen outcome measures. **Economic Analysis** Alongside the statistical analysis plan, a Health Economics Analysis Plan (HEAP) will be produced setting out the objectives, methods and plans for dissemination of the health economics findings.⁴⁴ The costing of the development of the ThinkCancer! Intervention will include researcher time, piloting, materials development, printing, publication, development of online materials, etc. Delivery costs of the ThinkCancer! Intervention will be determined based on the following: Online delivery format – live seminars/webinars, staff time and materials, exploration of whether health professional time should be collected in a full trial to reflect the co-production nature of CPD in own time or reflecting the opportunity cost of CPD in terms of time not spent on direct patient care activities. Mixed-format delivery – potential costs of a face-to-face/online delivery format across Wales in future after COVID-19. Qualitative analysis The transcribed telephone interviews, the free text responses from the feedback forms and the observational data, in text form, will be analysed for the process evaluation using Framework Analysis.⁴⁵ Framework is a five-

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

and ensuring the study adheres to the protocol.

stage matrix-based system for analysing qualitative data which is highly appropriate for a feasibility study which is iterative in its development. Initially all transcripts and textual data will be read thoroughly by the same researcher who conducted the interviews to achieve data familiarisation and immersion. An index of emergent themes will then be created and data coded according to the index. Charts will be created according to the themes and coded data will be synthesised into the appropriate thematic charts. The completed charts will then be used for final stage which is in-depth interpretation.⁴⁵ TRIAL MANAGEMENT The Sponsor is Bangor University. The study will be supported by the North Wales Organisation for Randomised Trials in Health (NWORTH), which is a fully registered Clinical Trials Unit. There will be no on-site monitoring as there are no local research teams at sites. Therefore, the monitoring of data will have a more internal focus in the form of self-audits to ensure compliance with regulations. **Trial governance** Operational group The operational working group will be responsible for the overall conduct, supervision and progress of the study. They consist of the immediate research team, supported by a wider group of experts. Trial Management group The Trial Management group (TMG) will meet once a month, consisting of the operational group and a wider team of experts, including a PPI member. The group will be responsible for the overall management of the trial,

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

Trial Governance Structure A Trial Steering Committee (TSC) committee will provide independent oversight for the study, ensuring it is conducted according to the standards set out by the HRA Research Governance Framework.⁴⁶ As the study includes an element of ongoing intervention refinement, and is deemed low risk with very minimal likelihood of stopping early due to patient safety, a Data Monitoring and Ethics Committee (DMEC) will not be required.⁴⁷ Meetings are expected to be biannual and the Sponsor and Funder will be updated following each meeting. The TSC will have an independent chairperson and at least three independent members including Patient and Public Involvement (PPI) representation, trial co-applicants, statisticians, health economist(s) and GPs. **Data Management** A detailed data management plan will be written by NWORTH staff. This plan will include the definition of the data quality checks that will be performed on the data throughout the life course of the trial. These will include source data validation, random data checks and timelines for data entry. Quality control Quality control will be maintained through adherence to the study protocol, Betsi Cadwaladr University Health Board/Bangor University Standard Operating Procedures (SOPs), principles of Good Clinical Practice, research governance and clinical trial regulations. Data protection and participant confidentiality All investigators, trial site and research staff will comply with the requirements and regulations of the EU General Data Protection Regulation 2018 (GDPR) regarding the collection, storage, processing and disclosure of personal information and will uphold the Regulation's core principles. All research staff involved will have up to date GCP training. Research data will be retained as per the Sponsor's research data management policy. Bangor University is the data custodian.

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

Data archiving As per the Sponsor's research data management policy, research data and records will be archived along with the data management policy of the Sponsor. In line with legal requirements, trial documents will be archived centrally at a secure facility with appropriate environmental controls and adequate protection from fire, flood and unauthorized access. Archived material will be stored in tamper-proof archive boxes that are clearly labelled. Electronic archiving will be provided by the Sponsor for post-project deposit and retention of data. Destruction of essential documents will require authorisation from the Sponsor. **Dissemination policy** On completion of the study a final report will be prepared for Cancer Research Wales. Findings will be disseminated through various media, including open-access peer-reviewed publications, national and international conferences, the programme web pages, social media, and through an end-of-programme symposium for key stakeholders. Findings will also be disseminated to participating practice teams. Publications arising directly from the WICKED programme and authorship on the final trial report will adhere to the BMJ guidelines on authorship and contribution, based on the International Committee of Medical Journal Editors Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE) 2013.48 Patient and public involvement The study team recognises that the involvement of those with lived experiences will be vital in this research. Furthermore, a lay perspective is essential in the development and undertaking of research for the promotion of equality, diversity and transparency. Two patient representatives were initially recruited to the WICKED programme, one of whom has maintained active involvement in the study design, the development of the protocol and conduct throughout. Additionally, the trial PPI has been active in providing feedback on participantfacing documents. Two more PPI representatives have been recruited to the TSC through the North Wales Cancer Forum and have directly relevant experience. Their perspective as both a patient and a member of the public will inform the overall supervision of the trial.

DISCUSSION

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

This study aims to test the feasibility of the ThinkCancer! intervention. The ThinkCancer! Study comprises Work Package 4 (WP4) of a programme of research called the Wales Interventions and Cancer Knowledge about Early Diagnosis (WICKED). The intervention will consist of a workshop aimed at the entire general practice team, as previous work packages have demonstrated the value of a whole-practice approach. If the intervention is shown to be feasible, we will proceed with designing a full-scale definitive trial. This trial is especially relevant due to the current ongoing Covid-19 pandemic, which has had a major negative impact on suspected cancer referrals to secondary care, and will likely delay many cancer diagnoses and treatments, leading to poorer patient outcomes. One of the key strengths of this intervention is that it can be iteratively developed throughout the study period, which will ensure the future definitive trial will adopt an optimal approach. The design process of the study is also a strength in that a strong multidisciplinary team and advisory groups have been involved throughout. Furthermore, the mixed methods approach will allow us to capture a variety of data from this complex intervention. Furthermore, the planned rigour with which the study will be conducted is also a strength. We are aware that some challenges in the recruitment lay ahead, but we plan to work with the various research infrastructures in Wales to overcome this. We plan to work closely with the Primary Care Specialty Lead and Primary Care Research Managers within Health and Care Research Wales, as well as with the individual health board R&D departments in order to maximise recruitment. We will also work closely with the

practices that agree to take part in order to support their participation in the study.

Although safety-netting has garnered more attention in recent years, there currently are no recommendations on how best to do it.²⁶ To our knowledge, there are no interventions targeting primary care with a focus on safety netting. In addition, involving the entire practice is a relatively novel approach, with great potential benefit. This study encompasses a multicomponent and complex behavioural change intervention comprising a multidimensional, interactive, tailored and whole-practice approach, which is timely and needed to optimise primary care approaches to the timely diagnosis of cancer.

TRIAL STATUS

567

568

569

570

571

572

573

574

575

576

577

The trial is currently open for recruitment.

ABBREVIATIONS

578	2WW	Two Week Wait
579	AE	Adverse Event
580	CSNC	Cancer Safety Netting Champion
581	CSNP	Cancer Safety Netting Plan
582	DMEC	Data Monitoring and Ethics Committee
583	GCP	Good Clinical Practice
584	GDPR	General Data Protection Regulations
585	GP	General Practitioner
586	HCSW	Health Care Support Worker
587	НЕАР	Health Economics Analysis Plan
588	HRA	Health Research Authority
589	MRC	Medical Research Council

590	NIHR	National Institute for Health Research			
591	NWORTH	North Wales Organisation for Randomisation Trials in Health			
592	PCI	Primary Care Interval			
593	PCP	Primary Care Provider			
594	PIS	Participant Information Sheet			
595	PPI	Patient and Public Involvement			
596	R&D	Research and Development			
597	RCT	Randomised Controlled Trial			
598	RISP	Research Information Sheet for Practices			
599	REC	Research Ethics Committee			
600	SAE	Serious Adverse Event			
601	SOP	Standard Operating Procedures			
602	TSC	Trial Steering Committee			
603	WICKED	Wales Interventions and Cancer Knowledge about Early Diagnosis			
604	WP	Work Package			
605					
606	DECLARATIONS				
607	Ethics approve	al and consent to participate			
608	This study has been approved by the Health Research Authority/Health and Care Research Wales (IRAS 256824)				
609	and Bangor University (School of Healthcare Sciences, 2019-16498). We did not seek REC Approval; this was				
610	not required as the study does not involve patients.				

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

Participants are consented at two different time points in the study. Practice managers will consent to participate in the study on behalf of the general medical practice. If the practice has been randomised to the intervention, individual staff participants will be asked for their informed consent at the start of the workshop. **Trial Sponsor** Bangor University. The Sponsor had no role in the design of this trial and will not have any role during its execution, analyses, data interpretation or decision to submit results. Contact: Dr Huw Roberts. School of Healthcare Sciences, The Normal Site, Holyhead Road, Gwynedd, LL57 2AS, UK; Tel: 01248 383 136; Email: huw.roberts@bangor.ac.uk **Consent for publication** No participant identifiable information will be published. Availability of data and materials On completion of the trial, the final datasets generated and/or analysed will be available from the corresponding author on reasonable request. Access to the final datasets will be in accordance with governance policies, Good Clinical Practice (GCP) guidelines and funder arrangements. **Competing interests** The authors declare that they have no competing interests. **Funding** This article presents independent research funded by Cancer Research Wales (CRW). The views expressed are those of the authors and not necessarily those of CRW. This funding source had no role in the design of this trial and will not have any role during its execution, analyses, data interpretation or decision to submit results. This research is also linked to the CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385), of which RDN is an Associate Director.

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

read and approved the final manuscript.

Indemnity Bangor University currently has in place appropriate Clinical Trials Indemnity and Professional Indemnity insurance covering harm to participants arising from the management and/or the design of the research and member of the research team to conduct the research as per protocol. On sites that are not covered by the NHS Indemnity Scheme (e.g. GP surgeries in primary care), investigators/collaborators will need to ensure that their activity on the study is covered under their own professional indemnity. Health and Care Research Wales assisting with recruitment will have NHS contracts and will be responsible for ensuring they are appropriately insured. **Authors' contributions** RDN and CW are the Chief Investigators for the study. CW and RDN contributed to all aspects of this work including: conceiving and design of the study, obtaining initial and additional funding, intervention development, management of the study, obtaining approvals and writing the report. SD is the Research Project Support Officer for the study. SD drafted the manuscript integrating comments from JR, AS, AH, NG, CW, RN, NW, RTE, BFA, RL, RJL, and ACS. SD was also involved in the development of the intervention and its adaptation in response to COVID-19. AS was involved in the development of the intervention, its adaptation in response to COVID-19 and contributed to the protocol via the intervention description and by developing the logic model. AS also read and approved the final manuscript. The workshop materials were designed by AS, with assistance and advice from the wider ThinkCancer! team. AS is also the GP Educator and will be delivering the intervention. JR is the trial manager for the study. She oversaw the writing of the protocol, facilitated gaining approvals from the seven health boards and contributed to adaptations of the methodology in response to COVID-19. JR also

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

AH is the qualitative researcher for the study and contributed to the protocol via the embedded qualitative component and design of qualitative data collection materials. AH also contributed to gaining R&D approvals from the seven health boards. AH also read and approved the final manuscript. RL was involved in the development of the intervention, the study design and the previous work packages leading up to the ThinkCancer trial. RL contributed to the methodological components of the protocol. RL read and approved the final manuscript. NG is the Trial Statistician and contributed to the protocol via the statistical component. NG also read and approved the final manuscript. ZH is the Principal Statistician and will oversee all statistical analysis. ZH was involved in the design of the study and contributed to the protocol via the statistical component and the outcome measures. ZH read and approved the manuscript. RTE is Lead Health Economist. BFA is Health Economics Research Support Project Officer and drafted the health economics analysis plan and is responsible for data analysis. RTE and BFA read and approved the manuscript. RJL was involved in the intervention development and the previous work packages leading up to the ThinkCancer trial. RJL read and approved the final manuscript. JH was involved in the intervention development and the previous work packages leading up to the ThinkCancer trial. JH read and approved the final manuscript. ACS contributed to the design of the study and the development of the intervention. ACS also read and approved the final manuscript. **Acknowledgements** The authors would like to thank Maggie Hendry for her significant contributions to the trial protocol on which this paper is based, as well as her contributions to the development of the intervention, and Stella Wright, for her contributions to the trial protocol and the participant-facing materials. We would also like to acknowledge Nic Nikolic for her work on the study costings. We would like to thank Jan Rose, Brian Lewin and Rosemary

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

Birch, our patient representatives, for their valuable contributions to the development of the protocol and the participant-facing materials. We would also like to acknowledge the contributions from Dr Jane Heyhoe from the Yorkshire and Humber Patient Safety Translational Research Centre and Dr Caroline Green from RedWhale GPUpdate. **ADDITIONAL MATERIALS** Additional file 1: WHO Trial Registration Data Set (Additional File 1 – WHO trial registration data.pdf) Additional file 2: ThinkCancer! Logic Model (Additional File 2 – logic model.pdf) Additional file 3: participant flow diagram (Additional File 3 – participant flow diagram.pdf) Additional file 4: SPIRIT Checklist (Additional File 4 – SPIRIT.pdf) **REFERENCES** 1. CRUK. Cancer Research UK position paper: The diagnostic workforce in Wales. 2018; https://www.bsg.org.uk/wp-content/uploads/2020/02/Cancer-Research-UK-position-paper-on-the-diagnosticworkforce-in-Wales.pdf?x83412, 2019. 2. Nicholson BD, Mant D, Neal RD, Hart N, Hamilton W, Shinkins B, et al. International variation in adherence to referral guidelines for suspected cancer: a secondary analysis of survey data. British Journal of General Practice 2016;66(643):106-113. 3. Wales Cancer Network. Cancer Delivery Plan for Wales 2016-2020. 2016; http://www.walescanet.wales.nhs.uk/sitesplus/documents/1113/161114cancerplanen.pdf, 2019. 4. Rose PW, Rubin G, Perera-Salazar R, Almberg SS, Barisic A, Dawes M, et al. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. BMJ Open 2015;5(5):e007212.

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

5. Butler J, Foot C, Bomb M, Hiom S, Coleman M, Bryant H, et al. The International Cancer Benchmarking Partnership: an international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. Health Policy 2013;112(1-2):148-155. 6. Rubin GP, Berendsen A, Crawford M, Dommett R, Earle C, Emery J, et al. The expanding role of primary care in cancer control. The Lancet Oncology 2015;16(12):1231-1272. 7. Hamilton W, Walter FM, Rubin G, Neal RD. Improving early diagnosis of symptomatic cancer. Nature Reviews: Clinical Oncology 2016;13(12):740-749. 8. Koo MM, Hamilton W, Walter FM, Rubin GP, Lyratzopoulos G. Symptom signatures and diagnostic timeliness in cancer patients: A review of current evidence. Neoplasia 2018;20(2):165-174. 9. WHO. Key statistics. 2020; https://www.who.int/cancer/resources/keyfacts/en/. Accessed 12th October, 2020. 10. Weller D, Menon U, Falborg AZ, Jensen H, Barisic A, Knudsen AK, et al. Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open 2018;8(11):e023870. 11. Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. The Lancet 2020;21(603):748-749. 12. Looi M, Coombes R. Risky Business: lessons from covid-19. BMJ 2020;369:m2221. 13. Spicer J, Chamberlain C, Papa S. Provision of cancer care during the COVID-19 pandemic. Nature Reviews Clinical Oncology 2020;17(6):329-331.

14. Lai A, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH, et al. [In press] Estimating excess mortality in 719 720 people with cancer and multimorbidity in the COVID-19 emergency. 2020; 721 https://www.researchgate.net/publication/340984562_Estimating_excess_mortality_in_people_with_cancer_ 722 and multimorbidity in the COVID-19 emergency/citation/download. 723 15. Hiom S. How coronavirus is impacting cancer services in the UK. 2020; 724 https://scienceblog.cancerresearchuk.org/2020/04/21/how-coronavirus-is-impacting-cancer-services-in-the-725 uk/. Accessed 20, 2020. 726 16. Wise J. Covid-19: Cancer mortality could rise at least 20% because of pandemic, study finds. BMJ 727 2020;369:m1735. 728 17. Round T. Primary care and cancer: Facing the challenge of early diagnosis and survivorship. European 729 Journal of Cancer Care 2017;26(3):e12703. 730 18. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al. The Aarhus Statement: improving design 731 and reporting of studies on early cancer diagnosis. Br J Cancer 2012;106:1262-1267. 732 19. Evans J, Ziebland S, MacArtney JI, Bankhead CR, Rose PW, Nicholson BD. GPs' understanding and practice of 733 safety netting for potential cancer. British Journal of General Practice 2018;68(672):505-511. 734 20. Mansell G, Shapley M, Jordan JL, Jordan K. Interventions to reduce primary care delay in cancer referral: a 735 systematic review. British Journal of General Practice 2011;61(593):821-835. 736 21. Baskerville NB, Liddy C, Hogg W. Systematic review and meta-analysis of practice facilitation within primary care settings. Annals of Family Medicine 2012;10(1):63-74. 737 738 22. Schichtel M, Rose PW, Sellers C. Educational interventions for primary healthcare professsionals to promote

the early diagnosis of cancer: a systematic review. Education for Primary Care 2013;24(4):274-290.

739

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

23. Blank L, Baxter S, Woods HB, Goyder E, Lee A, Payne N, et al. Referral interventions from primary to specialist care: a systematic review of international evidence. British Journal of General Practice 2014;64(629):765-774. 24. Nicholson BD, Mant D, Bankhead C. Can safety-netting improve cancer detection in patients with vague symptoms? BMJ Quality & Safety. BMJ Quality & Safety 2016;355:i5515. 25. Rubin GP, Saunders CL, Abel GA, McPhail S, Lyratzopoulos G, Neal RD. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. BJC 2015;112(4):676-687. 26. Jones D, Dunn L, Watt I, Macleod U. Safety netting for primary care: evidence from a literature review. BJGP 2019;69(678):e70-e79. 27. NICE. Suspected cancer: recognition and referral (NG12). 2015; https://www.nice.org.uk/guidance/ng12 https://www.nice.org.uk/guidance/ng12, 2019. 28. Stanciu MA, Law RJ, Nafees S, Hendry M, Yeo ST, Hiscock J, et al. Development of an intervention to expedite early cancer diagnosis through primary care. BMJ Open 2018;2(3). 29. Eldridge S, Lancaster G, Campbell M, Thabane L, Hopewell S, Coleman C, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE 2016;11(3):e0150205. 30. Craig P, Dieppe P, Macintryre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655.

31. NIHR. NIHR Research for Patient Benefit (RfPB) Programme Guidance on Applying for Feasibility Studies. 759 760 2017; https://www.nihr.ac.uk/funding-and-support/documents/funding-for-research-studies/research-761 programmes/RfPB/Guidance%20Documents/Guidance_on_feasibility_studies.pdf, 2019. 762 32. Lancaster G, Dodd S, Williamson P. Design and analysis of pilot studies: recommendations for good practice. 763 J Eval Clin Pract 2004;10(2):307-312. 764 33. Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions. UK Medical Research Council (MRC) guidance. 2015; https://mrc.ukri.org/documents/pdf/mrc-765 766 phsrn-process-evaluation-guidance-final/, 2019. 767 34. Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: 768 Defining standard protocol items for clinical trials. Ann Intern Med 2013;158(3):200-207. 769 35. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: 770 extension to randomised pilot and feasibility trials. BMJ 2016 Oct 24,;355:i5239. 771 36. NCIN. General Practice Profiles for cancer: Meta-data for profile indicators. 2010; 772 https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=2ahUKEwj8wL 773 KNhuHgAhUL4OAKHfZfBBEQFjAAegQlCRAC&url=http%3A%2F%2Fncin.org.uk%2Fview.aspx%3Frid%3D90&usg= 774 AOvVaw1MczVZD_U_jHJXJtu9W2mP, 2019. 775 37. Meechan D, Gildea C, Hollingworth L, Richards MA, Riley D, Rubin G. Variation in use of the 2-week referral 776 pathway for suspected cancer: a cross-sectional analysis. The British journal of general practice: the journal of 777 the Royal College of General Practitioners 2012;62(602):e590-e597.

38. DIRUM. Database of Instruments for Resource Use Measurement. 2019; http://www.dirum.org/about,

778

779

2019.

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

39. Russel D, Hoare ZSJ, Whitaker R, Whitaker CJ, Russel IT. Generalized method for adaptive randomization in clinical trials. Statist Med 2011;30:922-934. 40. Kaplan H, Provost L, Froehle C, Margolis P. The Model for Understanding Success in Quality (MUSIQ): building a theory of context in healthcare quality improvement. BMJ Quality & Safety 2012;21(1):13-20. 41. Kirkpatrick Partners. The Kirkpatrick Model. 2019; https://www.kirkpatrickpartners.com/Our-Philosophy/The-Kirkpatrick-Model, 2019. 42. May C, Rapley T, Mair FS, Treweek S, Murray E, Ballini L, et al. The Normalization Process Theory On-Line User's Manual, Toolkit and NoMAD instrument. 2015; http://www.normalizationprocess.org. 43. ICH-GCP. CH E6 Good Clinical Practice (GCP) Guideline. 2016; https://www.ema.europa.eu/en/ich-e6-r2good-clinical-practice, 2019. 44. Thorn JC, Brookes ST, Ridyard C, Riley R, Hughes DA, Wordsworth S, et al. Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey. Value in Health 2018;21(6):640-649. 45. Ritchie J, Spencer L, O'Connor W. Carrying out Qualitative Analysis. In: Ritchie J, Lewis J, editors. Qualitative Research Practice. A guide for social science students and researchers London: SAGE Publications Ltd; 2003. 46. HRA. UK Framework for Health and Social Care Research. 2017; https://www.hra.nhs.uk/planning-andimproving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/, 2019. 47. EMEA. Guideline on data monitoring committees. 2005; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-monitoringcommittees en.pdf, 2019.

48. International Committee of Medical Journal Editors (ICMJE). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Updated December 2019. 2013. [accessed 27 Nov 2020] Available from: http://www.icmje.org/recommendations/

799

800

801

802